Shareholders in Phathom Pharmaceuticals (NASDAQ:PHAT) Have Lost 66%, as Stock Drops 12% This Past Week

Simply Wall StDec 14 22:34

Do You Believe in the Growth Potential of Phathom Pharmaceuticals (PHAT)?

Yahoo FinanceDec 12 22:39

Phathom Pharmaceuticals Analyst Ratings

BenzingaDec 12 02:08 · Ratings

Needham Maintains Phathom Pharmaceuticals(PHAT.US) With Buy Rating, Maintains Target Price $28

Futu NewsDec 12 01:32 · Ratings

Phathom Pharmaceuticals: Undervalued Opportunity With Strategic Moves for Extended Exclusivity

TipRanksDec 12 00:55

Express News | Phathom Pharmaceuticals Inc: Exclusivity Period Is Until May 3, 2032

BreakingsDec 11 21:03